La patère du Musée de Vierzon

Dr Denys TIXIDRE, La Patère du Musée de Vierzon. Cette patère en bronze coulé, et vraisemblablement autrefois argentée, s'avère être un très bel objet signé « JANVARIS », nom d'un fondeur lyonnais du Ier siècle de notre ère. Ce document entre dans la série des « Têtes de Cygne » ; le manche ciselé en relief représente deux têtes de bélier, le coq chantant, le canard en vol, la tortue, le casque du guerrier, la chouette, une lyre et un. pinson encadrant la balance renversée, enfin les deux têtes de cygne et la signature de l'orfèvre « JANVARIS ».Tixidre Denys. La patère du Musée de Vierzon. In: Revue archéologique du Centre, tome 4, fascicule 2, 1965. pp. 165-168

Prise en charge médico-pharmaceutique des sportifs de haut niveau

Bien que les écarts de niveau soient flagrants entre un sportif professionnel et un sportif amateur, il n'en demeure pas moins qu'il ne faudra pas négliger la santé de ces athlètes. De nombreux jeunes ou moins jeunes ont sacrifié leur santé pour la pratique d'un sport qu'ils considéraient comme une passion sans se soucier des conséquences physiques et se préoccupant parfois plus des performances et des profits à réaliser. Ainsi, il est intéressant d'étudier la prise en charge médicale des sportifs et la gestion des médicaments au sein des clubs de sport. Nous verrons qu'elle implique de nombreux professionnels de santé dont on évoquera le rôle. Le pharmacien étant un professionnel de santé absent du staff médical des clubs de sport de haut niveau, nous allons mettre en évidence les atouts qu'il pourrait apporter pour améliorer cette prise en charge médico-pharmaceutique des sportifs de haut niveau.CLERMONT FD-BCIU-Santé (631132104) / SudocLYON1-BU Santé (693882101) / SudocSudocFranceF

ETUDE DE PHASE II DE L'ASSOCIATION ACIDE FOLINIQUE-5 FLUOROURACILE-GEMCITABINE-OXALIPLATINE (FOLFU-GEMOX) CHEZ DES PATIENTS ATTEINTS DE CANCERS DU PANCREAS LOCALEMENT AVANCES ET METASTATIQUES

GRENOBLE1-BU Médecine pharm. (385162101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

L'Église et le monastère de Sainte-Florine / Docteur Denys Tixidre

Contient une table des matièresAvec mode text

Feasibility and efficacy of a supervised home-based physical exercise program for metastatic cancer patients receiving oral targeted therapy: study protocol for the phase II/III - UNICANCER SdS 01 QUALIOR trial

International audienceBackground: Currently, oral targeted therapies are known to be effective and are frequently used to treat metastatic cancer patients, but fatigue is a frequently reported early side effect of these treatments. This fatigue may impact the patient’s treatment adherence and result in a negative impact on quality of life. Physical exercise significantly improved the general well-being and quality of life of advanced cancer patients. However, there is no specific physical activity program adapted for patients with advanced disease. Methods QUALIOR is a two-part, randomized, open-label, and multicenter with two arms phase II/III trial. Patients (phase II: n = 120; phase III: n = 312) with metastatic cancer (breast cancer, kidney cancer, lung cancer, and other cancers [including but not limited to colon cancer, melanoma, sarcoma, or hepatocarcinoma]) treated with a first- or second-line oral targeted therapy without chemotherapy will be included. Patients will be randomized (2:1) to a 3-month supervised home-based standardized physical activity program or to a recommended adapted physical activity (via a booklet). The primary objective of the phase II is to evaluate the feasibility of the supervised program. The primary objective of the phase III is the evaluation of the benefit of the supervised home-based program compare to the recommended program in terms of fatigue and quality of life at 3 months. The secondary objectives aim to evaluate the impact of the supervised program on fatigue over time, pain, physical capacities, psychosocial and cognitive functions, general quality of life, frequency of dose reduction and patients’ adherence to the targeted therapy, overall survival, and progression-free survival. This study will also evaluate the medico-economic impact of supervised program compared to the recommended adapted physical activity program. Discussion The aim of this study is to evaluate home-based physical exercise program for metastatic cancer patients treated with oral targeted therapies to help patients to cope with fatigue and improve quality of life. Trial registration This trial was registered in ClinicalTrials.gov since May 2017 ( NCT03169075 )

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

International audienceIntroduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the French real-world setting.Patients and Methods: Eligible patients were aged ≥ 18 years with planned bevacizumab-containing therapy for newly diagnosed ovarian cancer. The primary objective was to assess the safety profile of front-line bevacizumab in routine clinical practice; secondary objectives were to describe patient characteristics, indications/contraindications for bevacizumab, treatment regimens and co-medications, follow-up and monitoring, progression-free survival, and treatment at recurrence. In this non-interventional study, treatment was administered as chosen by the investigator and participation in the trial had no influence on the management of the disease.Results: Of 1,290 patients screened between April 2013 and February 2015, 468 were eligible. Most patients (86%) received bevacizumab 15 mg/kg every 3 weeks or equivalent, typically with carboplatin (99%) and paclitaxel (98%). The median duration of bevacizumab was 12.2 (range 0–28, interquartile range 6.9–14.9) months; 8% of patients discontinued bevacizumab because of toxicity. The most common adverse events were hypertension (38% of patients), fatigue (35%), and bleeding (32%). There were no treatment-related deaths. Most physicians (90%) reported blood pressure measurement immediately before each bevacizumab infusion and almost all (97%) reported monitoring for proteinuria before each bevacizumab infusion. Median progression-free survival was 17.4 (95% CI, 16.4–19.1) months. The 3-year overall survival rate was 62% (95% CI, 58–67%). The most commonly administered chemotherapies at recurrence were carboplatin and pegylated liposomal doxorubicin.Discussion: Clinical outcomes and tolerability with bevacizumab in this real-life setting are consistent with randomized trial results, notwithstanding differences in the treated patient population and treatment schedule